Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldurazyme Immunogenicity and GAG Levels in MPS I
NCT00144768Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jul 2004
- Primary completion
- May 2007
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of laronidase in mucopolysaccharidosis type I, sponsored by Sanofi. Primary endpoints: Urinary glycosaminoglycans up to 4 years and Immunogenicity Testing up to 4 years. Started Jul 2004; status: completed.
02
Drugs
laronidase
03
Conditions
mucopolysaccharidosis type I
Beyond the preview
Go deeper on NCT00144768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144768.